This study is for adults with certain blood cancers called B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma (LBL). These cancers affect the white blood cells. The study compares two treatments: one using a special drug called inotuzumab ozogamicin with lower-dose chemotherapy, and the other using usual chemotherapy. Inotuzumab ozogamicin is a targeted therapy; it finds and kills cancer cells by attaching to their CD22 receptors. Chemotherapy can kill or stop cancer cells from growing and spreading.

Key Points:

• The study involves a series of visits for treatment cycles that repeat every 28 days and can last up to 2 years.
• Participants must be at least 50 years old and meet certain health criteria.
• There is potential for side effects, such as liver problems or other toxicities, which will be monitored during the study.

Participants will have regular follow-ups after treatment ends to check on their health. This study aims to see if the combination of inotuzumab ozogamicin with chemotherapy works better than usual chemotherapy alone.